Speaker Profile

M.D., Ph.D., Associate Director for Translational Research, The Rutgers Cancer Institute of New Jersey

Dr. Ganesan is Associate Director for Translational Research and Chief of the Section of Molecular Oncology at the Rutgers Cancer Institute of New Jersey. His research focus on the role of genomic instability and epigenetic instability in cancer, and the use of cancer genomics for cancer classification and treatment. His laboratory contributed to better understanding of the roles of BRCA1 and 53BP1 in DNA repair choice . His recent work has focused on novel genomic markers of response and resistance to chemotherapy, targeted therapy and immunotherapy. In the clinic, Dr. Ganesan takes care of patients with breast cancer and rare cancer , is the co-Leader of the Clinical Investigations and Precision Therapeutics program and runs the molecular tumor board at RCINJ. He has authored or co-authored over 100 peer-reviewed publications. Dr. Ganesan received his undergraduate education at Princeton, his M.D. and Ph.D. at Yale, and his clinical training at the Brigham and Women’s Hospital and Dana Farber Cancer Institute.

 Session Abstract – PMWC Silicon Valley

The Molecular Tumor Board (MTB) was mostly established to facilitate the incorporation of molecular diagnostics into the consideration of appropriate therapies for patients with late stage cancer. Initially, much of the deliberation was focused on understanding the results of such testing, as reporting of results was limited in scope and frequently understandable only to cutting edge experts in the field. Improved, but still not perfect, reporting now exists, so discussion has shifted to prognostic and therapeutic considerations. That said, the collective experience with rare mutations and off label therapies is still such that collective wisdom is necessary. This brings up the issue of how MTBs collect, share, and preserve data within a specific MTB, and perhaps more importantly, how it might be shared amongst MTBs and beyond. While initial activity related to MTBs resided almost exclusively in large academic, and select community, medical centers, there is now significant effort in the commercial setting as well, with a number of intriguing efforts presently underway. Important and evolving issues, such as defining which patients are most likely to benefit from the efforts of a MTB, Virtual MTBs, and the generation of Real World Evidence, will be discussed.